The Evolution of Triamcinolone Acetonide Therapeutic Use in Retinal Diseases: From Off-Label Intravitreal Injection to Advanced Nano-Drug Delivery Systems

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Jul 29

PMID 37509540

Authors

Luis Abraham Aceves-Franco

Oscar Eduardo Sanchez-Aguilar

Allen Rafael Barragan-Arias

Marco Antonio Ponce-Gallegos

Jose Navarro-Partida

Arturo Santos

Affiliations

Soon will be listed here.

Abstract

Ophthalmic drug delivery to the posterior segment of the eye has been challenging due to the complex ocular anatomy. Intravitreal injection of drugs was introduced to deliver therapeutic doses in the posterior segment. Different posterior segment diseases including age-related macular degeneration, diabetic macular edema, retinal vein occlusions, uveitis, and cystoid macular edema, among others, have been historically treated with intravitreal corticosteroids injections, and more recently with intravitreal corticosteroids drug implants. Triamcinolone acetonide (TA) is the most frequently used intraocular synthetic corticosteroid. Using nanoparticle-based TA delivery systems has been proposed as an alternative to intravitreal injections in the treatment of posterior segment diseases. From these novel delivery systems, topical liposomes have been the most promising strategy. This review is oriented to exhibit triamcinolone acetonide drug evolution and its results in treating posterior segment diseases using diverse delivery platforms.

Citing Articles

Efficacy and safety of dexamethasone or triamcinolone in combination with anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis with trial sequential analysis.

Zhou B, Liu H, Xiong F PLoS One. 2025; 20(2):e0318373.

PMID: 39919066 PMC: 11805578. DOI: 10.1371/journal.pone.0318373.

Efficacy of different routes of triamcinolone acetonide administration on macular edema: A systematic review and network meta-analysis.

Liu K, Yi J, Xu J, Zhong L, Su N PLoS One. 2025; 20(1):e0317782.

PMID: 39854565 PMC: 11760001. DOI: 10.1371/journal.pone.0317782.

Nanomedicine in Ophthalmology: From Bench to Bedside.

Mahaling B, Baruah N, Dinabandhu A J Clin Med. 2025; 13(24.

PMID: 39768574 PMC: 11678589. DOI: 10.3390/jcm13247651.

Geraniin Alleviates Mouse Laser-Induced Choroidal Neovascularisation by Inhibiting Choroidal Endothelial Cell ACE2/Ang-(1-7)/MasR/IL-10 Pathway.

Lu H, Cai Q, Li L, Gu J, Zhang Y, Sun H J Cell Mol Med. 2024; 28(23):e70228.

PMID: 39622780 PMC: 11611526. DOI: 10.1111/jcmm.70228.

Efficacy and safety of intravitreal conbercept and triamcinolone acetonide for wet age-related macular degeneration in China: a meta-analysis.

Yang F, Hu R Int Ophthalmol. 2024; 44(1):424.

PMID: 39527325 PMC: 11554939. DOI: 10.1007/s10792-024-03346-9.

References

Ozkok A, Saleh O, Sigford D, Heroman J, Schaal S . THE OMAR STUDY: Comparison of Ozurdex and Triamcinolone Acetonide for Refractory Cystoid Macular Edema in Retinal Vein Occlusion. Retina. 2015; 35(7):1393-400. DOI: 10.1097/IAE.0000000000000475. View

Wingate R, Beaumont P . Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol. 2000; 27(6):431-2. DOI: 10.1046/j.1440-1606.1999.00238.x. View

Navarro-Partida J, Castro-Castaneda C, Santa Cruz-Pavlovich F, Aceves-Franco L, Guy T, Santos A . Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases. Pharmaceutics. 2021; 13(5). PMC: 8151015. DOI: 10.3390/pharmaceutics13050678. View

Abdelshafy Tabl A, Tawfik Soliman T, Elsayed M, Abdelshafy Tabl M . A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane. J Ophthalmol. 2022; 2022:7947710. PMC: 8799353. DOI: 10.1155/2022/7947710. View

Cho H, Kambhampati S, Lai M, Zhou L, Lee G, Xie Y . Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy. Adv Ther (Weinh). 2021; 4(2). PMC: 8436818. DOI: 10.1002/adtp.202000181. View

Khalil M, Hashmi U, Riaz R, Abbas S . Chitosan coated liposomes (CCL) containing triamcinolone acetonide for sustained delivery: A potential topical treatment for posterior segment diseases. Int J Biol Macromol. 2019; 143:483-491. DOI: 10.1016/j.ijbiomac.2019.10.256. View

Zhang D, Che D, Zhu D . A simple technique for suprachoroidal space injection of triamcinolone acetonide in treatment of macular edema. Int J Ophthalmol. 2022; 15(12):2017-2021. PMC: 9729086. DOI: 10.18240/ijo.2022.12.18. View

Maggio E, Mete M, Polito A, Parrozzani G, Pertile G . Retrobulbar triamcinolone for inflammatory choroidal neovascularization in pregnancy. BMC Ophthalmol. 2020; 20(1):483. PMC: 7727127. DOI: 10.1186/s12886-020-01759-5. View

Spandau U, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas J . Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol. 2005; 89(8):999-1003. PMC: 1772791. DOI: 10.1136/bjo.2004.062596. View

10.

Araujo J, Garcia M, Mallandrich M, Souto E, Calpena A . Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomedicine. 2011; 8(6):1034-41. DOI: 10.1016/j.nano.2011.10.015. View

11.

Jonas J, Degenring R, Kamppeter B, Kreissig I, Akkoyun I . Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol. 2004; 138(1):158-60. DOI: 10.1016/j.ajo.2004.02.025. View

12.

Spandau U, Sauder G, Schubert U, Hammes H, Jonas J . Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo. Br J Ophthalmol. 2005; 89(6):745-7. PMC: 1772672. DOI: 10.1136/bjo.2004.052563. View

13.

Kaur I, Kakkar S . Nanotherapy for posterior eye diseases. J Control Release. 2014; 193:100-12. DOI: 10.1016/j.jconrel.2014.05.031. View

14.

Jonas J, Degenring R, Kreissig I, Friedemann T, Akkoyun I . Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye (Lond). 2004; 19(2):163-70. DOI: 10.1038/sj.eye.6701438. View

15.

Jonas J, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R . Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol. 2003; 87(4):462-8. PMC: 1771586. DOI: 10.1136/bjo.87.4.462. View

16.

Sutter F, Simpson J, Gillies M . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004; 111(11):2044-9. DOI: 10.1016/j.ophtha.2004.05.025. View

17.

Patel A, Cholkar K, Agrahari V, Mitra A . Ocular drug delivery systems: An overview. World J Pharmacol. 2015; 2(2):47-64. PMC: 4289909. DOI: 10.5497/wjp.v2.i2.47. View

18.

Bakri S, Ekdawi N . Intravitreal silicone oil droplets after intravitreal drug injections. Retina. 2008; 28(7):996-1001. DOI: 10.1097/IAE.0b013e31816c6868. View

19.

Navarro-Partida J, Altamirano-Vallejo J, Aceves Franco L, Gonzalez-Cortes J, Mota S, Garcia-Aguirre J . Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. Pharmaceutics. 2021; 13(9). PMC: 8471461. DOI: 10.3390/pharmaceutics13091491. View

20.

Benz M, Murray T, Dubovy S, Katz R, Eifrig C . Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol. 2003; 121(2):271-3. DOI: 10.1001/archopht.121.2.271. View